版本:
中国

Nektar's opioid painkiller succeeds in key late-stage study

March 20 Nektar Therapeutics said its experimental opioid, designed to achieve pain relief minus the high levels of euphoria that can lead to abuse and addiction with existing opioids, succeeded in a key late-stage study.

The drug, which by design reaches the brain slower than existing opioids to deter abuse, outperformed a placebo in over 600 patients with chronic lower back pain. (Reporting by Natalie Grover in Bengaluru; Editing by Anil D'Silva)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐